GEORGE R BLUMENSCHEIN to Administration, Oral
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Administration, Oral.
Connection Strength
0.186
-
Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun; 20(6):859-69.
Score: 0.070
-
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008 Feb; 26(1):81-7.
Score: 0.055
-
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80.
Score: 0.023
-
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. 2011 Jun; 29(3):499-505.
Score: 0.016
-
Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6.
Score: 0.011
-
Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 06; 242(1):49-52.
Score: 0.008
-
Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981; 18(2):163-72.
Score: 0.002